Modifiable Major Risk Factors

Slide 1 · Modifiable Major Risk Factors

Atherosclerosis • Mechanisms, vascular pathology, and risk integration

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish modifiable from constitutional atherosclerotic risk factors.

Explain how LDL, vascular injury, smoking, diabetes, and inflammation promote atherogenesis.

Relate risk-factor control to plaque progression and major clinical complications.

Interpret textbook risk estimates without confusing distinct endpoints.

Slide 3 · Atherosclerosis is the disease context

Major modifiable exposures converge on an intimal plaque

Atheromas contain lipids, inflammatory cells, smooth muscle cells, and extracellular matrix.

Plaques may narrow the lumen or undergo disruptive change followed by thrombosis.

Clinical territories include coronary, cerebral, and peripheral arteries.

Slide 4 · Modifiable versus constitutional risk

Potentially modifiable

Constitutional

Hyperlipidemia

Genetic susceptibility and family history

Hypertension

Increasing age

Cigarette smoking

Sex-related risk patterns

Diabetes and its metabolic effects

Neither category acts in isolation

Inflammation: Mechanistic target/context

Risk management remains relevant at any baseline risk

Slide 5 · The major risk-factor framework

Lipid abnormalities, hypertension, cigarette smoking, and diabetes as major modifiable risks.

The chapter’s risk-factor table also lists inflammation under modifiable factors.

Systemic risk factors act within a locally susceptible arterial wall.

Risk factors often act synergistically rather than independently.

Slide 6 · From systemic exposure to vascular disease

Risk-factor exposure

Endothelial dysfunction

Intimal lipid and cell accumulation

Atheromatous plaque

Stenosis or plaque complication

Multiple exposures can converge on common pathways; No single factor determines every lesion.

Slide 7 · Why risk factors matter before symptoms

Lesion development precedes many clinical events

Atherosclerosis is progressive and may be clinically silent for years.

An obstructive plaque limits perfusion; A disrupted plaque can precipitate thrombosis.

Risk reduction can mitigate risk even when elimination of exposure is incomplete.

Slide 8 · Lipid abnormalities: The central risk factor

Hyperlipidemia, especially hypercholesterolemia, is a major atherosclerosis risk factor.

Hypercholesterolemia alone can initiate lesion development in the absence of other risks.

LDL cholesterol is the serum-cholesterol component most strongly linked to increased risk.

Circulating lipoprotein concentrations and composition both matter.

Slide 9 · How LDL delivers cholesterol

Liver and circulation

LDL in blood

Peripheral tissue delivery

Potential arterial-wall accumulation

LDL is a protein–lipid–cholesterol complex that transports cholesterol to peripheral tissues.

Slide 10 · Evidence that LDL is atherogenic

Cholesterol and cholesterol esters dominate the lipid component of plaques.

Inherited defects of lipoprotein uptake can accelerate atherosclerosis.

Population analyses link increasing LDL or total cholesterol with greater lesion burden.

Reducing serum cholesterol slows progression and lowers cardiovascular event risk.

Slide 11 · How LDL becomes trapped within arteries

Increased LDL burden

Intimal lipoprotein retention

Oxidation or aggregation

Macrophage uptake

Lipid-filled foam cells

Modified LDL uptake fosters lipid-laden foam cells and an inflammatory response.

Slide 12 · LDL oxidation and local injury

Reactive oxygen species can promote LDL oxidation within the intima.

Modified LDL is toxic to endothelial cells and other arterial-wall cells.

Macrophage uptake uses scavenger receptors, distinct from the conventional LDL receptor.

Persistent uptake contributes to intracellular lipid accumulation.

Slide 13 · Where circulating LDL becomes plaque lipid

LUMEN

INTIMA

MEDIA

Cap

Lipid core

LDL retained in the intima

Lipid-rich plaque core

Plaque encroaches on lumen

Underlying arterial media

Slide 14 · Foam-cell formation creates early lesions

Modified LDL

Scavenger receptor uptake

Macrophage lipid accumulation

Foam cell

Fatty streak

Foam cells may derive from macrophages; Vascular smooth muscle cells may also accumulate lipids.

Slide 15 · LDL receptor versus scavenger uptake

Conventional LDL uptake

Modified-lipid uptake

LDL receptor mediates uptake of circulating LDL.

Macrophages use scavenger receptors for altered LDL.

Hepatic receptor function is key to LDL clearance.

Sustained modified-lipid ingestion produces foam cells.

Defective receptor function elevates LDL levels.

The cell response contributes to local inflammation.

Slide 16 · Familial LDL-receptor dysfunction

An inherited risk factor exposes the causal role of LDL

Loss-of-function LDL-receptor mutations diminish hepatic uptake and catabolism.

Severe receptor defects lead to markedly elevated LDL and accelerated atherosclerosis.

This mechanism links genetic susceptibility to a treatable lipid phenotype.

Slide 17 · HDL: Reverse cholesterol transport

HDL mobilizes cholesterol from peripheral tissues, including atheromas.

It transports cholesterol to the liver for catabolism and biliary excretion.

Higher circulating HDL levels correlate with lower cardiovascular risk.

Association between HDL concentration and risk does not alone establish a therapeutic target.

Slide 18 · Reverse cholesterol transport concept

Peripheral cholesterol

HDL-mediated mobilization

Transport to liver

Catabolism and biliary excretion

HDL’s role contrasts with LDL delivery of cholesterol to peripheral tissues.

Slide 19 · LDL and HDL have different roles

LDL cholesterol

HDL cholesterol

Delivers cholesterol to peripheral tissues.

Mobilizes cholesterol from peripheral tissues.

Elevated LDL is causally linked to plaque development.

Higher HDL level correlates with lower risk.

Lowering LDL is associated with fewer events.

Exclusively raising HDL has not yielded expected benefit.

Slide 20 · HDL: A biomarker is not always a target

Raising HDL concentration alone is not an effective strategy

Higher HDL levels associate with less risk, but correlation need not imply that increasing HDL concentration reduces events.

Ineffective HDL-raising approaches with demonstrated LDL-lowering benefits.

Avoid equating favorable laboratory change with proven clinical benefit.

Slide 21 · Dyslipoproteinemia is heterogeneous

Increased LDL cholesterol is the dominant lipid-associated major risk factor.

Low HDL can be part of an atherogenic lipid phenotype.

The adjacent pathogenesis section also describes elevated lipoprotein(a).

Secondary disorders may influence lipid patterns, including diabetes and hypothyroidism.

Slide 22 · Dietary lipids: The source’s distinctions

Textbook-described favorable feature

Textbook-described unfavorable feature

Omega-3 fatty acids are considered beneficial.

Artificially hydrogenated trans-unsaturated fats can worsen cholesterol profiles.

Overall diet effects should not be reduced to one nutrient.

Most other dietary fat effects as smaller than previously assumed.

Actual risk reduction requires attention to the lipid profile.

Do not infer drug-equivalent benefits from diet statements.

Slide 23 · Intervening on the lipid pathway

Dietary and pharmacologic LDL-lowering interventions have clinical relevance.

Lowering cholesterol may slow plaque progression and permit regression of some lesions.

Effects on cardiovascular events are more important than biomarker changes alone.

Mechanisms of cholesterol reduction differ among intervention classes.

Slide 24 · Statins target cholesterol synthesis

Statin administration

HMG-CoA reductase inhibition

Reduced hepatic cholesterol synthesis

Lower circulating cholesterol

Statins inhibit the rate-limiting enzyme in hepatic cholesterol biosynthesis.

Slide 25 · What the textbook attributes to statins

Statins are widely used to lower circulating cholesterol.

Their use is associated with reduced rates of myocardial infarction.

Robbins also considers anti-inflammatory effects as possible contributors to benefit.

Lipid reduction remains the established therapeutic mechanism discussed here.

Slide 26 · PCSK9 drives LDL-receptor degradation

PCSK9 binds LDL receptor

Receptor degradation accelerates

Fewer receptors available

Circulating LDL rises

PCSK9 increases degradation of LDL receptors, thereby tending to raise LDL cholesterol.

Slide 27 · Blocking PCSK9 lowers LDL

Inhibition of PCSK9

Less receptor degradation

More LDL-receptor availability

Lower circulating LDL

Loss-of-function PCSK9 variants and PCSK9 inhibitors support the receptor-clearance mechanism.

Slide 28 · Statin and PCSK9 strategies

Statin strategy

PCSK9 inhibitor strategy

Primary site: Hepatic synthesis.

Primary site: LDL-receptor fate.

Mechanism: Inhibits HMG-CoA reductase.

Mechanism: Prevents PCSK9-driven receptor degradation.

Textbook cites fewer myocardial infarctions.

Textbook cites marked LDL reduction.

Slide 29 · Two therapeutic levers for LDL

Production and clearance are distinct control points

Statin: Reduce hepatic cholesterol biosynthesis.

PCSK9 inhibition: Preserve LDL receptors and promote receptor-mediated LDL removal.

Both change LDL biology; The extracted passage provides no dosing or patient-selection algorithm.

Slide 30 · Hypertension: A major arterial insult

Hypertension is a major modifiable risk factor for atherosclerotic disease.

Chronic pressure stress affects vascular function and promotes arterial injury.

Endothelial dysfunction facilitates lipoprotein entry and leukocyte recruitment.

Blood-pressure control is part of multifactorial risk reduction.

Slide 31 · Pressure burden and plaque susceptibility

Sustained high pressure

Vascular/endothelial injury

Permeability and cell adhesion

Plaque-promoting environment

Hypertension contributes alongside lipids and inflammation rather than acting as an isolated plaque pathway.

Slide 32 · Hypertension and ischemic heart disease

~60%

Higher ischemic heart disease risk

Textbook comparison: Hypertension versus normotension

Hypertension can increase the risk by approximately 60%.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Slide 33 · Left ventricular hypertrophy: Risk context

Chronic hypertension is the most common cause of left ventricular hypertrophy.

The hypertrophied ventricle reflects sustained pressure loading.

Left ventricular hypertrophy as a surrogate marker of cardiovascular risk.

Hypertrophy should not be confused with an atherosclerotic plaque itself.

Slide 34 · Hypertension and the two vascular phenotypes

Atherosclerotic large-vessel disease

Hypertensive arteriolar disease

Intimal atheroma formation and complications.

Small-artery/arteriolar wall changes.

Hypertension is one contributor among several.

Hyaline or hyperplastic arteriolosclerosis.

Clinical consequences include ischemic events.

Can cause parenchymal ischemia, especially renal.

Slide 35 · Why coexisting hypertension and dyslipidemia matter

LDL supplies a substrate for intimal lipid accumulation.

Hemodynamic stress worsens endothelial susceptibility.

Inflammatory cell recruitment amplifies lesion progression.

Addressing only one factor leaves other pathogenic inputs active.

Slide 36 · Cigarette smoking: A strong acquired risk

Prolonged cigarette exposure substantially elevates ischemic heart disease mortality.

Cigarette-smoke toxins contribute to endothelial dysfunction.

The duration of exposure matters comparison.

Smoking cessation materially reduces the associated risk.

Slide 37 · Tobacco exposure and the vessel wall

Cigarette-smoke toxins

Endothelial dysfunction

Inflammatory / thrombotic susceptibility

Accelerated vascular injury

Smoke exposure is one of several contributors to endothelial injury in the response-to-injury framework.

Slide 38 · Long-term smoking and IHD mortality

2×

Death rate

Textbook comparison: Prolonged cigarette smoking

An approximately doubled death rate from ischemic heart disease.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Slide 39 · Smoking cessation changes risk

A behavioral exposure is biologically and clinically reversible in part

Smoking cessation substantially reduces the elevated ischemic heart disease risk.

Reduction is meaningful even after years of exposure.

The source passage does not specify a timeline for risk normalization.

Slide 40 · Smoking is not just a lipid exposure

Endothelial toxins act even without isolated hypercholesterolemia.

Adverse vascular effects intersect with leukocyte adhesion and thrombosis.

Tobacco and elevated LDL can operate simultaneously.

Risk-factor inventories should identify smoking independently of lipid measurements.

Slide 41 · Exposure assessment versus tissue consequence

Exposure history

Vascular pathology

Active cigarette smoking and years of exposure.

Endothelial dysfunction is a mechanistic connection.

Cessation is a modifiable intervention.

Intimal inflammation helps plaque progression.

No safe threshold is established by the supplied passage.

Clinical event risk reflects multiple concurrent factors.

Slide 42 · Diabetes creates an atherogenic milieu

Diabetes as a major modifiable atherosclerotic risk condition.

Diabetes can induce hypercholesterolemia and interact with other lipid abnormalities.

Hyperglycemia is included among stimuli that promote endothelial dysfunction.

Diabetic vascular risk extends beyond the coronary circulation.

Slide 43 · Metabolic disease and intimal injury

Diabetes / hyperglycemia

Dyslipidemia plus endothelial stress

Inflammatory cellular recruitment

Accelerated plaque burden

The relationship is multifactorial: Lipid alteration and endothelial stress can occur together.

Slide 44 · Diabetes and myocardial infarction

2×

Incidence

Textbook comparison: Diabetes versus normoglycemia

All other factors being equal, twice the incidence of myocardial infarction.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Slide 45 · Diabetes extends risk to the brain

Stroke is part of the macrovascular disease burden

An increased stroke risk in people with diabetes.

Stroke can reflect atherosclerotic involvement in cerebral arteries.

Consider coronary, cerebral, and peripheral arterial outcomes separately.

Slide 46 · Diabetes and lower-extremity gangrene

100×

Textbook-reported risk

Outcome: Atherosclerosis-induced lower-extremity gangrene

A 100-fold increased risk; The extracted passage does not define the study population.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Slide 47 · Diabetes: Large-vessel versus small-vessel effects

Macrovascular / atherosclerotic

Microvascular / metabolic context

Accelerated atheroma formation.

Hyperglycemia influences vascular tissues.

Increased myocardial infarction incidence.

Specific microangiopathic complications are outside this unit.

Increased stroke and ischemic limb complications.

Do not equate all diabetic vascular injury with atherosclerosis.

Slide 48 · A clinical lipid result needs metabolic context

The same measured LDL level may occur in different clinical risk settings.

Diabetes is itself a major risk condition, not merely an LDL value.

Smoking and blood pressure alter the patient’s overall risk profile.

Risk assessment should integrate exposures, diseases, and their interactions.

Slide 49 · Inflammation is integral to atherogenesis

The textbook’s major-risk table includes inflammation.

Activated macrophages and T lymphocytes contribute to plaque progression.

Cholesterol crystals can activate innate immune inflammatory pathways.

Inflammatory signaling can amplify endothelial activation and leukocyte recruitment.

Slide 50 · Lipid accumulation activates inflammation

Modified LDL and cholesterol crystals

Macrophage innate immune sensing

Inflammasome activation

Proinflammatory cytokine signaling

Further leukocyte recruitment

Inflammation is both a response to lipids and an amplifier of plaque growth.

Slide 51 · Inflammatory markers require interpretation

CRP is an acute-phase protein primarily produced by the liver.

CRP as an independent marker of cardiovascular-event risk.

The text distinguishes risk prediction from a direct causal role for CRP.

CRP may decline with smoking cessation, weight loss, exercise, or statin use.

Slide 52 · Inflammation: Mediator versus marker

Mechanistic mediators

Clinical marker: CRP

Macrophage activation and cytokine release.

Associates with risk for vascular events.

Intimal leukocyte recruitment.

Not established as a direct causal factor in this text.

Plaque progression and potential destabilization.

A measured biomarker is not synonymous with a treatment target.

Slide 53 · How risk factors converge in a mature plaque

LUMEN

INTIMA

MEDIA

Cap

Lipid core

Fibrous tissue caps the plaque

Cells and cytokines promote growth

Necrotic lipid-rich center

Underlying arterial media

Slide 54 · Why the combined risk is substantial

Conventional factors are not independent biological silos.

Lipid retention, endothelial dysfunction, and inflammation reinforce one another.

Risk-factor effects are often more than additive.

Risk reduction across several domains mitigates cumulative disease burden.

Slide 55 · Major factors: Primary pathways

Factor

Major contribution

Key source-linked teaching point

High LDL

Intimal lipid loading

Direct atherogenic role

Hypertension

Endothelial/hemodynamic stress

LV hypertrophy as risk marker

Smoking

Toxic endothelial injury

Cessation lowers risk

Diabetes

Metabolic and endothelial injury

Coronary + peripheral risk

Inflammation

Cell recruitment and signaling

Mechanism ≠ CRP causation

Slide 56 · The main modifiable pathways

Reduce LDL burden

Control pressure

Stop cigarette exposure

Manage diabetic metabolic risk

Multiple interventions address different components of atherogenesis; Exact treatment thresholds are outside the source excerpt.

Slide 57 · Risk modification is not a guarantee

What intervention can do

What intervention cannot promise

Mitigate cumulative risk.

Eliminate constitutional susceptibility.

Reduce progression and selected events.

Reverse every established plaque.

Remove or lower important exposures.

Guarantee freedom from events.

Target several biologic pathways.

Replace comprehensive clinical evaluation.

Slide 58 · Case: Isolated severe cholesterol elevation

CLINICAL SCENARIO

A young adult has markedly elevated LDL cholesterol but reports no tobacco use and has no known hypertension or diabetes. A parent experienced premature coronary disease.

Can high LDL alone initiate atherogenesis, and what additional mechanism is suggested?

Slide 59 · Case: Elevated pressure and ventricular hypertrophy

CLINICAL SCENARIO

A middle-aged adult has longstanding hypertension and echocardiographic left ventricular hypertrophy. LDL is mildly elevated; Smoking history is negative.

What does the hypertrophy represent, and why is atherosclerotic risk still elevated?

Slide 60 · Case: Long smoking exposure

CLINICAL SCENARIO

A patient with many years of cigarette smoking asks whether quitting can still help, despite an established atherosclerotic plaque.

Which source-based risk conclusion is appropriate?

Slide 61 · Case: Diabetes with leg ischemia

CLINICAL SCENARIO

A person with diabetes develops exertional leg pain and reduced distal arterial pulses. Lipid measurements are available, but the clinician also considers diabetes-specific vascular risk.

Which major-risk factor is operative, and what clinical territory matters?

Slide 62 · Case: Interpreting a high HDL value

CLINICAL SCENARIO

A patient’s HDL concentration increased after an intervention, but LDL remains elevated. The intervention has not demonstrated a reduction in cardiovascular events.

Why is an HDL increase insufficient evidence of benefit?

Slide 63 · Synthesis: Substrate, injury, and amplification

Atherosclerosis is produced by interacting processes

Lipid: Retained and modified LDL supplies plaque cholesterol.

Injury: Pressure, smoke toxins, and metabolic disease influence the endothelium.

Inflammation: Recruited cells and mediators amplify lesion progression.

Slide 64 · Recap: Exposure and intervention

Risk exposure or condition

Source-grounded modification

Elevated LDL cholesterol

LDL-lowering therapies and dietary measures

High blood pressure

Blood-pressure control

Cigarette smoking

Smoking cessation

Diabetes

Control of the metabolic disorder

Slide 65 · Final clinicopathologic points

Hypercholesterolemia is capable of initiating atherosclerosis even without other classic risks.

Hypertension, smoking, and diabetes add substantial vascular risk through distinct but overlapping mechanisms.

Statin and PCSK9 pathways illustrate two LDL-lowering mechanisms.

Risk estimates refer to different endpoints; Integrate them clinically rather than multiplying them.

Slide 66 · Primary reference and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease

11th edition (2026), Chapter 11: Blood Vessels

Modifiable Major Risk Factors, pp. 449–451

Mechanistic context: adjacent atherosclerosis risk-factor and pathogenesis sections